Excalibur Fund Managers

Excalibur Group Holdings, based in London, is a venture capital firm with a strong focus on life sciences, biotechnology, and medical devices. Established in 1996, the firm has built a reputation for bridging the gap between research and commercialization, providing both early and late-stage capital. Excalibur plays an active role in developing cutting-edge therapies, diagnostics, and healthcare technologies. Their investment strategy targets companies that are innovating in critical areas such as oncology, therapeutic devices, and laboratory services. The firm has made over 59 investments, with notable companies like Celsis International, NeoGen, and Selah Genomics. Excalibur's investments span various stages, from early ventures to generating revenue, and their portfolio emphasizes transformative healthcare solutions. They have also facilitated numerous successful exits, including companies like Plethora Solutions and Celsis In Vitro. Excalibur's approach is highly strategic, supporting startups not just with capital but also by offering market access and strategic advice, positioning them for acquisitions or public listings. This makes Excalibur a critical player in the European life sciences venture space, known for its ability to take healthcare innovations from the lab to the marketplace.